N
IRLA

Natixis’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Natixis’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-31
Closed -$306K – 1095
2020
Q3 		$306K Sell
31
-30
-49% -$273K ﹤0.01% 658
2020
Q2 		$564K Sell
61
-22
-27% -$202K ﹤0.01% 601
2020
Q1 		$757K Buy
83
+23
+38% +$227K 0.01% 519
2019
Q4 		$674K Sell
60
-3
-5% -$18.1K ﹤0.01% 684
2019
Q3 		$315K Buy
+63
New +$388K ﹤0.01% 723

Other funds holding IRLA

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SUT
SC US (TTGP) Menlo Park, California $31.9B AUM 28.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PHAM
Pacific Heights Asset Management San Francisco, California $3.16B AUM 42.38% 1-Year Est. Return

Natixis's IRLA Position: Q4 2020 in Review

Natixis sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q4 2020, closing a stake of 31 shares — an estimated $306K sold.

Natixis first reported a position in IRLA in Q3 2019 and held it in 5 quarters. The position peaked at $757K in Q1 2020. 84 funds tracked by Wall St. Rank hold IRLA as of Q4 2020.

  • Natixis reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Natixis sold 31 IRulya Therapeutics Inc. Common Stock shares in Q4 2020, an estimated $306K.
  • Natixis first reported a position in IRulya Therapeutics Inc. Common Stock in Q3 2019 and held it in 5 quarters.
  • Natixis's IRulya Therapeutics Inc. Common Stock position peaked at $757K in Q1 2020.
  • 84 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q4 2020.

Based on Natixis's 13F filing for Q4 2020, filed 12 Feb 2021.